BIONTECH SE (BNTX) Social Stream



BIONTECH SE (BNTX): $186.13

-11.89 (-6.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BNTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 495

in industry

Featured Post From StockTwits About BNTX

$BNTX "We will need a third dose": Pfizer's vaccine co-founder admits annual vaccination
Scientist argues that new doses allow "to increase immunity again and bring it closer to 100%".

"We will need a third dose, to increase immunity again and bring it closer to 100%." The statement is from Ugur Sahin, co-founder of the German company BioNTech, which developed the Pfizer vaccine.
The scientist said, in a virtual meeting with foreign correspondents in Germany, that immunity decreases over time and advised a third dose between nine months and a year after taking the second dose of the vaccine.
Like other scientists, Sahin also believes that doses will be needed annually or every year and a half to ensure protection against Covid-19, just as with flu vaccines.
The Pfizer vaccine was the first to be approved for commercial use. It is administered in two doses 21 days apart and guarantees an estimated immunity of 95%.
HHilel, published April 28, 2021

What Else are BNTX Traders Talking About?


Other tickers frequently mentioned alongside BNTX are AZN, JNJ, PFE and MRNA.

Other Notable StockTweets About BNTX


$BNTX The EU deal for 1,8B doses for 2022 and 2023 has a value of 42.3B$ if the price is the same as the new deal for Israel witch was 19.5Euro / 23.5$ pr.dose.

42.3B$ 50/50 split with Pfizer = 21.1B$
what gives us a revenue of 10.5B$ for 900mill doses in 2022 and 10.5B$ for 900mill doses 2023.

Pfizer/BioNTech production forecast:
2021 2,5B doses 1.5B direct contracts 400mill options
600mill negotiation
2022 3B doses 900mill direct EU contract "10million Israel"
2.1B doses negotiation
2023 ?B doses 900mill direct EU contract

JAXI7, published April 23, 2021

$BNTX ATH, exceeding BB, RSI on the daily at 83, stochastics at 99...pull back ahead folks. Don't take it personal, those are facts and you can either trade them or watch your gains melt. Your decision. Good luck everyone.

ChipFlipper, published April 19, 2021

$BNTX This is on the same level as CCP propaganda /North Korea mind control disinformation campaign. I now lost all respect for $AZN , Oxford, and anyone else associated with this study probably $JNJ too. $PFE was incredibly smart teaming up with Biontech and took a huge risk not taking OWS money (in hindsight they and Biontech probably should have like $MRNA did) and now as a last gasp for air, the losers feel the need to cast their last stones. Remember, $JNJ has been killing women for decades with their asbestos laced talc baby powder. Cant trust these guys and their old technology

https://www.marketwatch.com/story/blood-clots-as-prevalent-with-pfizer-and-moderna-vaccine-as-with-astrazenecas-report-2021-04-15

Texas12, published April 15, 2021

$BNTX "Brussels chooses pharmaceutical company to produce 1.8 billion vaccines against variants" - 2

"Taking into account the experience we already have in terms of acquisition agreements, creation of a vaccine portfolio and accelerated production", this contract to be signed with only one pharmaceutical company provides for the initial purchase of 900 million doses and with the option to buy another 900 million, the same source explained to Lusa, after the information was advanced by the French news agency AFP.
It is stipulated that "in the next few days" the community executive will choose a pharmaceutical company that works with messenger RNA technology - such as Pfizer / BioNTech or Moderna -, and then the company will make an offer, which will be negotiated between the parties, providing in particular "monthly obligations" for delivery (instead of quarterly, as currently).
Only after the invitation did they start negotiations with that same pharmaceutical company,

HHilel, published April 10, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7249 seconds.